Hai Ge Shen
Corporate Officer/Principal en Genfleet Therapeutics (Shanghai), Inc. .
Perfil
Hai Ge Shen currently works as a Senior Vice President-Clinical Development at Genfleet Therapeutics (Shanghai), Inc.
Cargos activos de Hai Ge Shen
| Empresas | Cargo | Inicio |
|---|---|---|
Genfleet Therapeutics (Shanghai), Inc.
 Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Commercial Services |
- Bolsa de valores
- Insiders
- Hai Ge Shen
